Compare Stocks: PBM, ABVC, ALGS, and ATNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.05 -1.9%	$1.36	$0.88 ▼ $3.40	$27.88M	0.57	103,461 shs	7,489 shs
ALGS Aligos Therapeutics	$4.86 +2.3%	$5.35	$3.98 ▼ $13.69	$30.08M	2.31	157,963 shs	21,573 shs
ATNM Actinium Pharmaceuticals	$0.75 -8.0%	$0.98	$0.74 ▼ $1.81	$23.37M	-0.02	141,009 shs	102,835 shs
PBM Psyence Biomedical	$3.23 +1.3%	$3.23	$1.92 ▼ $34.63	$7.41M	1.66	1.21 million shs	15,489 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+2.88%	+0.94%	-40.56%	-2.73%	-66.56%
ALGS Aligos Therapeutics	+3.26%	+11.76%	-15.03%	-25.43%	-40.63%
ATNM Actinium Pharmaceuticals	-0.18%	-6.52%	-17.43%	-34.68%	-51.20%
PBM Psyence Biomedical	+1.27%	+0.95%	+4.93%	-46.21%	-88.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.05 -1.9%	$1.36	$0.88 ▼ $3.40	$27.88M	0.57	103,461 shs	7,489 shs
ALGS Aligos Therapeutics	$4.86 +2.3%	$5.35	$3.98 ▼ $13.69	$30.08M	2.31	157,963 shs	21,573 shs
ATNM Actinium Pharmaceuticals	$0.75 -8.0%	$0.98	$0.74 ▼ $1.81	$23.37M	-0.02	141,009 shs	102,835 shs
PBM Psyence Biomedical	$3.23 +1.3%	$3.23	$1.92 ▼ $34.63	$7.41M	1.66	1.21 million shs	15,489 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+2.88%	+0.94%	-40.56%	-2.73%	-66.56%
ALGS Aligos Therapeutics	+3.26%	+11.76%	-15.03%	-25.43%	-40.63%
ATNM Actinium Pharmaceuticals	-0.18%	-6.52%	-17.43%	-34.68%	-51.20%
PBM Psyence Biomedical	+1.27%	+0.95%	+4.93%	-46.21%	-88.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	710.53% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	517.28% Upside
PBM Psyence Biomedical	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PBM, ABVC, ALGS, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	PBM Psyence Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/29/2026	ALGS Aligos Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
5/28/2026	ALGS Aligos Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$45.00
5/21/2026	ALGS Aligos Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
5/21/2026	ALGS Aligos Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
5/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	55.70	N/A	N/A	$0.52 per share	2.06
ALGS Aligos Therapeutics	$2.19M	13.43	N/A	N/A	$8.67 per share	0.55
ATNM Actinium Pharmaceuticals	$90K	282.38	N/A	N/A	$1.31 per share	0.62
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	$7.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.40	N/A	N/A	N/A	N/A	-62.46%	-39.99%	8/18/2026 (Estimated)
ALGS Aligos Therapeutics	-$24.19M	-$8.69	N/A	N/A	N/A	-1,919.68%	-139.47%	-90.88%	8/6/2026 (Estimated)
ATNM Actinium Pharmaceuticals	-$48.82M	-$0.75	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
PBM Psyence Biomedical	-$6.94M	$25.34	0.13	N/A	N/A	N/A	N/A	N/A	N/A

Latest PBM, ABVC, ALGS, and ATNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	N/A	N/A	N/A	$0.11 million	N/A
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	N/A	N/A	N/A	$24.68 million	N/A
6/22/2026	Q4 2026	PBM Psyence Biomedical	N/A	-$0.4050	N/A	-$0.4050	N/A	N/A
5/18/2026	Q1 2026	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
5/7/2026	Q1 2026	ALGS Aligos Therapeutics	-$2.29	-$2.21	+$0.08	-$2.21	$0.25 million	$2.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.12	0.12
ALGS Aligos Therapeutics	N/A	2.56	2.56
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
PBM Psyence Biomedical	N/A	14.62	14.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ALGS Aligos Therapeutics	60.43%
ATNM Actinium Pharmaceuticals	27.50%
PBM Psyence Biomedical	77.44%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ALGS Aligos Therapeutics	7.80%
ATNM Actinium Pharmaceuticals	0.60%
PBM Psyence Biomedical	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.55 million	21.51 million	Not Optionable
ALGS Aligos Therapeutics	90	6.19 million	5.71 million	No Data
ATNM Actinium Pharmaceuticals	30	31.38 million	29.32 million	Optionable
PBM Psyence Biomedical	N/A	2.29 million	2.21 million	N/A

PBM, ABVC, ALGS, and ATNM Headlines

Recent News About These Companies

Psyence Biomedical (NASDAQ:PBM) Stock Price Down 5.7% - Here's What Happened

August 1, 2026 | americanbankingnews.com

Psyence BioMed to Engage U.S. Stakeholders on Psychedelic Medicine Research and Ibogaine Supply Initiatives

May 15, 2026 | quiverquant.comQ

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

May 15, 2026 | globenewswire.com

Pacific Bay Adopts Semi-Annual Reporting

May 4, 2026 | newsfilecorp.comN

Psyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer Patients

April 23, 2026 | quiverquant.comQ

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

April 23, 2026 | financialpost.comF

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

April 23, 2026 | globenewswire.com

Why is PBM stock more than doubling premarket today?

April 20, 2026 | msn.com

Psyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

April 20, 2026 | financialpost.comF

Psyence Biomedical Ltd. Advances Strategic Position in Growing Ibogaine Market with Integrated GMP Manufacturing Platform

April 20, 2026 | quiverquant.comQ

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

April 20, 2026 | globenewswire.com

Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

April 17, 2026 | finanznachrichten.de

PBM stock on track for best session on report of upcoming Trump executive order on psychedelic ibogaine

April 17, 2026 | msn.com

PBM stock on track for best week in over 2 years on hopes for upcoming executive order to ease ibogaine research

April 17, 2026 | msn.com

Psyence Biomedical Ltd.

April 17, 2026 | cnn.com

Psyence Biomedical (PBM) Stock Soars 200%+ on White House Ibogaine Executive Order

April 17, 2026 | blockonomi.com

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

April 17, 2026 | financialpost.comF

Psyence Biomedical Ltd. Responds to Anticipated U.S. Executive Order on Ibogaine Research

April 17, 2026 | quiverquant.comQ

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

April 17, 2026 | globenewswire.com

Psyence Biomedical (PBM) soars 203.8% as micro-cap momentum builds around recent clinical-trial updates and corporate actions

April 16, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, ABVC, ALGS, and ATNM Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.05 -0.02 (-1.87%)

As of 10:24 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Aligos Therapeutics NASDAQ:ALGS

$4.86 +0.11 (+2.32%)

As of 10:12 AM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Actinium Pharmaceuticals NYSE:ATNM

$0.74 -0.07 (-8.02%)

As of 10:28 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Psyence Biomedical NASDAQ:PBM

$3.23 +0.04 (+1.25%)

As of 10:18 AM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBM, ABVC, ALGS, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBM, ABVC, ALGS, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBM, ABVC, ALGS, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, ABVC, ALGS, and ATNM Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Aligos Therapeutics NASDAQ:ALGS

Actinium Pharmaceuticals NYSE:ATNM

Psyence Biomedical NASDAQ:PBM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBM, ABVC, ALGS, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBM, ABVC, ALGS, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBM, ABVC, ALGS, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM, ABVC, ALGS, and ATNM Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Aligos Therapeutics NASDAQ:ALGS

Actinium Pharmaceuticals NYSE:ATNM

Psyence Biomedical NASDAQ:PBM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools